CAS 252979-43-4

N-[2-(2-Furyl)-8-propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N'-(4-methoxyphenyl)urea

Description:

N-[2-(2-Furyl)-8-propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N'-(4-methoxyphenyl)urea is a complex organic compound characterized by its unique structural features, which include a pyrazolo-triazolo-pyrimidine core and a urea functional group. This compound is notable for its potential biological activity, often investigated in the context of medicinal chemistry for its possible therapeutic applications. The presence of the furyl and methoxyphenyl substituents contributes to its chemical reactivity and solubility properties, which can influence its pharmacokinetics and pharmacodynamics. The compound's molecular structure suggests it may interact with specific biological targets, making it a candidate for further research in drug development. Additionally, its CAS number, 252979-43-4, allows for precise identification and retrieval of information related to its synthesis, properties, and applications in scientific literature. Overall, this compound exemplifies the intricate design often found in modern pharmaceutical agents, combining multiple heterocyclic systems to achieve desired biological effects.

Formula: C₂₁H₂₀N₈O₃

Synonyms:

• Mre-3008
• Mre-3008-F20

MRE3008F20

CAS: 252979-43-4

MRE3008F20

Purity: ≥95%

Molecular weight: 432.44g/mol

Ref: 54-BUP11549

MRE-3008F20

Controlled Product

CAS: 252979-43-4

Formula: C₂₁H₂₀N₈O₃

Color and Shape: Neat

Molecular weight: 432.435

Ref: TR-M750105

MRE-3008F20

CAS: 252979-43-4

MRE-3008F20 is a diagnostic agent that is used to determine the presence of cardiac or bowel disease in patients. It has also been shown to be effective against autoimmune diseases and cancer tissues, specifically targeting adenosine A3 receptors. MRE-3008F20 binds to these receptors and blocks the action of adenosine, which inhibits the release of substances that cause inflammation and pain. This drug has been shown to inhibit receptor activity in vitro and in vivo, as well as drug transporter function in vitro. MRE-3008F20 also has potent antagonist activity at p2y receptors, which are involved in inflammatory responses. This compound has been shown to have chemotherapeutic properties when used with other drugs such as doxorubicin or gemcitabine for treatment of cancer cells. The thermodynamic data and pharmacokinetic properties for MRE-3008F20 have not yet been determined.

Formula: C₂₁H₂₀N₈O₃

Purity: Min. 95%

Molecular weight: 432.44 g/mol

Ref: 3D-BM177371

MRE3008F20

CAS: 252979-43-4

MRE3008F20 is an AA3R antagonist that inhibits Cl-IB-MECA-induced cAMP production and can be used to study glaucoma and asthma.

Formula: C₂₁H₂₀N₈O₃

Purity: 97.29%

Color and Shape: Solid

Molecular weight: 432.44

Ref: TM-T16132